TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00078507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Re-training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Retraining
Description: Facial Exercises

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Opening Exercises
Study: NCT01407224

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Improve Early Breastfeeding
Description: One arm got only training, another arm training and supervision and third arm without any intervention as control.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improve Early Breastfeeding
Description: One arm got only training, another arm training and supervision and third arm without any intervention as control.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Improve Early Breastfeeding
Description: One arm got only training, another arm training and supervision and third arm without any intervention as control.
Study: NCT03585907

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MAD
Description: A high fat, low carbohydrate diet
Study: NCT02767076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound guided paramedian spinal anesthesia
Description: real time ultrasound guided paramedian spinal anesthesia
Study: NCT04015258

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberries
Description: fresh spanish blueberries

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry powder
Description: freeze-dried blueberry powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Blueberry components capsules
Description: encapsulated blueberry components (microcrystalline cellulose powder in actual)
Study: NCT01295710

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-ATG-F
Description: 20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
Study: NCT04864691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: endovascular recanalization
Description: to recanalize the occlusion cerebral artery with intravascular intervention

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: endovascular recanalization
Description: to recanalize the occlusion cerebral artery with intravascular intervention
Study: NCT01460563

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: 0.9% saline as same dose as MgSO4 as placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: 0.9% saline as same dose as MgSO4 as placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: 0.9% saline as same dose as MgSO4 as placebo
Study: NCT03585907

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MIND
Description: A combination of the Mediterranean and DASH diets
Study: NCT04794933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Study: NCT01155778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human heparan N-sulfatase (rhHNS)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human heparan N-sulfatase (rhHNS)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human heparan N-sulfatase (rhHNS)
Study: NCT00567476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Omalizumab 150 to 375 mg was administered subcutaneously every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of IgE.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled corticosteroids (ICS)
Description: Any ICS with proprietary drug and device \> 500 mcg of fluticasone or equivalent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled corticosteroids (ICS)
Description: Any ICS with proprietary drug and device \> 500 mcg of fluticasone or equivalent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long-acting beta 2-adrenergic agonist (LABA)
Description: Fixed dose of LABA as prescribed prior to study entry

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long-acting beta 2-adrenergic agonist (LABA)
Description: Fixed dose of LABA as prescribed prior to study entry

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short-acting beta 2-adrenergic agonist (SABA)
Description: Home use of nebulized Β2-agonist such as salbutamol 5 mg or terbutaline 10 mg for symptoms of intercurrent bronchospasm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short-acting beta 2-adrenergic agonist (SABA)
Description: Home use of nebulized Β2-agonist such as salbutamol 5 mg or terbutaline 10 mg for symptoms of intercurrent bronchospasm.
Study: NCT01922219

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy
Description: 14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks
Study: NCT03443518

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psoas Compartment Block (PCB)
Description: 30 ml of bupivacaine 0.25% will be infused over 3 minutes at the anatomical landmark for Psoas Compartment Block (PCB)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Anesthesia infiltration
Description: Lidocaine 5 ml of 2% will be injected subcutaneous as local infiltration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline 0.9% IV infusion
Description: Normal saline 0.9% IV infusion at the same rate of the Remifentanil infusion(0.05-0.1 μg/ kg/min).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Description: Remifentanil infusion with rate 0.03-0.1 μg/ kg/ min to achieve Visual Analog Scale (VAS) 3 or less
Study: NCT04206228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous iron isomaltoside
Description: The active drug, iron isomaltoside, will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (on-label treatment), over 30 minutes only (1,67 ml/min).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be prepared according to the randomisation code, and administered as a single intravenous infusion over 30 minutes only (1,67 ml/min).
Study: NCT04685694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: sl 800 mcg misoprostol
Study: NCT03994367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High animal protein isolate
Description: Increased dietary protein content from animal protein isolates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High animal protein whole food
Description: Increased dietary protein content from animal protein whole food

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High plant protein isolate
Description: Increased dietary protein content from plant protein isolates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High plant protein whole food
Description: Increased dietary protein content from animal protein whole food
Study: NCT00573170

Intervention type: DRUG
Group type: OTHER
Intervention: TREXIMET®
Description: Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate \[equivalent to sumatriptan 85mg\] and naproxen sodium 500mg)

Intervention type: DRUG
Group type: OTHER
Intervention: TREXIMET®
Description: Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate \[equivalent to sumatriptan 85mg\] and naproxen sodium 500mg)
Study: NCT04145492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2
Description: Patients will take 90 ug of vitamin K2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol (inactive vitamin D)
Description: Patients will take 10 ug of vitamin inactive vitamin D
Study: NCT00573170

Intervention type: DRUG
Group type: OTHER
Intervention: TREXIMET®
Description: Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate \[equivalent to sumatriptan 85mg\] and naproxen sodium 500mg)

Intervention type: DRUG
Group type: OTHER
Intervention: TREXIMET®
Description: Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate \[equivalent to sumatriptan 85mg\] and naproxen sodium 500mg)

Intervention type: DRUG
Group type: OTHER
Intervention: TREXIMET®
Description: Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate \[equivalent to sumatriptan 85mg\] and naproxen sodium 500mg)

Intervention type: DRUG
Group type: OTHER
Intervention: TREXIMET®
Description: Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate \[equivalent to sumatriptan 85mg\] and naproxen sodium 500mg)

Intervention type: DRUG
Group type: OTHER
Intervention: Butalbital-containing Combination Medications (BCM)
Description: butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg) \[currently marketed as Fioricet\]

Intervention type: DRUG
Group type: OTHER
Intervention: Butalbital-containing Combination Medications (BCM)
Description: butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg) \[currently marketed as Fioricet\]

Intervention type: DRUG
Group type: OTHER
Intervention: Butalbital-containing Combination Medications (BCM)
Description: butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg) \[currently marketed as Fioricet\]
Study: NCT04145492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol (inactive vitamin D)
Description: Patients will take 10 ug of vitamin inactive vitamin D

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2 and Cholecalciferol
Description: Patients will take 90 ug of vitamin K2 (MK-7) in addition 10 ug of vitamin inactive vitamin D
Study: NCT04794933

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT+ PNF in extremity pattern

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT+ PNF in extremity pattern

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT+ PNF in extremity pattern+PNF in scapula and upper trunk patterns
Study: NCT00713011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalat XL
Description: Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Adalat XL at a starting dose of 20 or 30 mg. Adalat XL will be titrated during the 18 week treatment period in order to optimize blood pressure. Adalat XL will be supplied in 20 mg, 30 mg, 60 mg, and 90 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiazac XC
Description: Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Tiazac XC at a starting dose of 180 mg. Tiazac XC will be titrated during the 18 week treatment period in order to optimize blood pressure. Tiazac XC will be supplied in 180 mg, 240 mg, 300 mg and 360 mg.
Study: NCT01561976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin hydrochloride prolonged release
Description: 1000mg in fasting state

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin hydrochloride prolonged release
Description: 1000mg in fed state

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin hydrochloride sustained release/Glimepiride
Description: 1000/2mg in fed state
Study: NCT01307449

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOVAX
Description: 1 dose of PNEUMOVAX

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOVAX
Description: 1 dose of PNEUMOVAX
Study: NCT04525846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFMT
Description: * program of PFMT consist of contract and hold pelvic floor muscle 10 seconds and relax 10 seconds 20 times per set totally 3 set per day~* follow up by telephone once a week about compliance of program PFMT, general symptoms, notice recording book~* at third trimester evaluate UI by questionaire (UDI-6, IIQ-7)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non PFMT
Description: Randomized to non PFMT group follow up and evaluate UI at third trimester sames as intervention group
Study: NCT00732381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Description: MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo nasal spray
Description: Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
Study: NCT03400969

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glycerol 17%
Description: Glycerol will be applied, using gauze on a lockable tweezer, at the end of the oral care procedure performed by a dentist.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aequasyal (OGT)
Description: Aequasyl (OGT) will be sprayed on the mucosa, at the end of the oral care procedure, preformed by a dentist.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Salient (new product)
Description: Salient (new Product) will be applied/given on a spoon, at the end of the oral care procedure, preformed by a dentist.
Study: NCT04507945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutritional Therapy, Metabolic Disorder, Regular
Description: According to the result reported by Byrne, Wilmore, etc. in 1992 \~ 1995, the use of growth hormone, glutamine, modified diet and other measures proposed intestinal rehabilitation treatment. Then, check the patient's quality of life survey, nutritional status, inflammation indicators and other changes every three months, and use metabolomics and microbiomic tools to detect changes in the patient's nutritional metabolism, intestinal microecology, etc., and adjust the patient's nutritional treatment and microecological treatment based on the results Program.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutritional Therapy, Metabolic Disorder, Regular
Description: According to the result reported by Byrne, Wilmore, etc. in 1992 \~ 1995, the use of growth hormone, glutamine, modified diet and other measures proposed intestinal rehabilitation treatment. Then, check the patient's quality of life survey, nutritional status, inflammation indicators and other changes every three months, and use metabolomics and microbiomic tools to detect changes in the patient's nutritional metabolism, intestinal microecology, etc., and adjust the patient's nutritional treatment and microecological treatment based on the results Program.
Study: NCT02852681

Intervention type: DRUG
Group type: OTHER
Intervention: 15 mg E4/3 mg DRSP
Description: All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (Sequence AB), or Treatment B followed by Treatment A (Sequence BA)

Intervention type: DRUG
Group type: OTHER
Intervention: 15 mg E4/3 mg DRSP
Description: All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (Sequence AB), or Treatment B followed by Treatment A (Sequence BA)
Study: NCT03546634

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sabin IPV
Description: We select one Sabin IPV product, produced by China National Biotec Group, which is available for China's National Immunization Program in the selected study sites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin IPV
Description: We select one Sabin IPV product, produced by China National Biotec Group, which is available for China's National Immunization Program in the selected study sites.
Study: NCT00573170

Intervention type: DRUG
Group type: OTHER
Intervention: Butalbital-containing Combination Medications (BCM)
Description: butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg) \[currently marketed as Fioricet\]

Intervention type: DRUG
Group type: OTHER
Intervention: Butalbital-containing Combination Medications (BCM)
Description: butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg) \[currently marketed as Fioricet\]
Study: NCT01307449

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: 1 dose of Prevnar

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: 1 dose of Prevnar
Study: NCT01585727

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME
Description: Total mesorectal excision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TME
Description: Total mesorectal excision

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromonitoring
Description: Intraoperative neuromonitoring of pelvic autonomic nerves.
Study: NCT00579644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination of Minocycline and MTX or MTX alone
Description: Methotrexate Dosing:~1)initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, increased to 15 mg/week.~3)4 month: dose of MTX will remain at its current level if full remission criteria are met; otherwise, be increased to 20 mg/week.~4)6, 8 and 10 month: If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week,dose will be increased to 20 mg/week. If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 5)12 month evaluation: End of the blinded portion of the study. minocycline dosage 200 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Initial evaluation: The dose of methotrexate for all patients will be 10 mg/week.~2 month evaluation: The dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, it will be increased to 15 mg/week.~4 month evaluation: The dose of MTX will remain at its current level if full remission criteria are met; otherwise, it will be increased to 20 mg/week.~6, 8 and 10 month evaluations:~If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week, the dose will be increased to 20 mg/week.~If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 12 month evaluation: End of the blinded portion of the study.
Study: NCT01688297

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-A1.1 Oral Vaccine
Description: One or two doses of replication incompetent adenovirus oral tablet vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-A1.1 Oral Vaccine
Description: One or two doses of replication incompetent adenovirus oral tablet vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-A1.1 Oral Vaccine
Description: One or two doses of replication incompetent adenovirus oral tablet vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: VXA Placebo Tablet
Description: Off-white tablets similarly formulated to the active drug product tablets.
Study: NCT02694666

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Controlled whole-body vibration training
Description: The intervention is an 8-week program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled whole-body vibration training
Description: The intervention is an 8-week program
Study: NCT01597258

Intervention type: DRUG
Intervention: Crizotinib (Xalkori)
Description: XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg This surveillance is all cases surveillance based on Japanese regulation. Frequency and duration are according to Package Insert as follows.  The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status.
Study: NCT03150238

Intervention type: OTHER
Intervention: observation of prognostic factors for relapse
Description: The identification of the most relevant prognostic factors and the definition of their weight in predict the risk of re-intervention will be the basis for the definition of a combined score
Study: NCT01779999

Intervention type: OTHER
Intervention: PICC-carrying patients
Description: Echographic monitoring of patients carrying a peripherally inserted central catheter
Study: NCT04134143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExpressGraft-C9T1 Skin Tissue
Description: A round patch of experimental skin tissue that the doctor applies over the ulcer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExpressGraft-C9T1 Skin Tissue
Description: A round patch of experimental skin tissue that the doctor applies over the ulcer
Study: NCT00573170

Intervention type: DRUG
Group type: OTHER
Intervention: Butalbital-containing Combination Medications (BCM)
Description: butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg) \[currently marketed as Fioricet\]

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: placebo
Study: NCT03662308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated Vest
Description: Heated vest that regulates its heat output based on the user's skin, the user's core temperature, and the ambient temperature

Intervention type: DEVICE
Group type: OTHER
Intervention: Heated Vest
Description: Heated vest that regulates its heat output based on the user's skin, the user's core temperature, and the ambient temperature

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Heated Vest
Description: A similarly insulated (compared to the experimental vest), but non-heated vest
Study: NCT02529202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine infusion
Study: NCT04290286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: i2TransHealth
Description: i2TransHealth: online intervention for TGD people